1Center of Hematological and Oncology,Beijing Children's Hospital, Capital Medical University,National Center for Children's Health,Beijing 100045,China; 2Center of Clinical Epidemiology and Evidence-Based Medicine,Beijing Children's Hospital,Capital Medical University,National Center for Children's Health,Beijing 100045,China; 3Department of Radiation Oncology,BeijingUnion Hospital,Chinese Academy of Medical Sciences,Beiijing 100730,China
Abstract：Objective To retrospectively analyze the clinical efficacy, safety and influencing factors of radiotherapy in children with stage Ⅳ high-risk neuroblastoma (HR-NB). Methods A total of 120 children with HR-NB who were diagnosed and treated with local radiotherapy according to the BCH-HR-NB-2007 protocol in the Oncology Department of Beijing Children's Hospital from January 2014 to December 2017 were enrolled. Among them, 56 children were male and 64 female with a median age of 43 months (9-148 months). The treatment protocol consisted of 4 cycles of CAV chemotherapy, 3 cycles of CVP chemotherapy, surgical resection after 4 cycles, autologous hematopoietic stem cell transplantation after 7 cycles, local radiotherapy at a dose of 15.0-30.6 Gy for 82 cases of primary tumors and 38 cases of primary and metastatic tumors, followed by 13 cis-retinoic acid as maintenance therapy. The entire treatment protocol endured for approximately 18 months. Results The median follow-up time was 21 months. The 3-year local control rate was 84.4%. Before radiotherapy, the 3-year event-free survival rate was 78.4% in children without metastases, significantly higher compared with 30.4% in the residual group (P=0.003). The 3-year event-free survival rate was 66.1% in patients who underwent radiotherapy within 6 months after surgery, significantly higher than 50.6% in their counterparts receiving radiotherapy at 6 months or more after surgery (P=0.018). Among the children with residual metastases before radiotherapy, the progression rate in children who did not receive radiotherapy was 66.6%, significantly higher compared with 20.0% in those receiving radiotherapy (P=0.001). All patients had no radiation-related adverse reactions in the liver, kidney and heart, etc. The incidence rate of grade Ⅲ-IV myelosupression was 24.5% at 1 week post-radiotherapy, and 8% at 2 weeks after radiotherapy. Conclusions Radiotherapy yields definite clinical efficacy in the local control of children with stage Ⅳ HR-NB. Early radiotherapy after surgery and radiotherapy for the metastatic lesions can improve the clinical prognosis. No vital organ injuries are observed during the short-term follow-up. At 2 weeks after radiotherapy, the myelosupression is gradually restored.
Zhou Yuchen,Su Yan,Jiang Chiyi et al. Analysis of clinical efficacy and safety of local radiotherapy in children with stage Ⅳ high-risk neuroblastoma[J]. Chinese Journal of Radiation Oncology, 2019, 28(4): 258-261.
[1] 马晓莉,金眉,张大伟,等.多学科联合诊治神经母细胞瘤91例临床特征及近期疗效分析[J].中华实用儿科临床杂志,2013,28(3):178-182.DOI:10.3760/cma.j.issn.2095-428X. 2013.03.007. Ma XL,Jin M,Zhang DW,et al. Clinical features and efficacy of recent treatment analysis of multimodality treatment for 91 children with neuroblastoma[J].Chin Clin J Pract Pediat,2013,28(3):178-182.DOI:10.3760/cma.j.issn.2095-428X.2013.03.007. [2] Kandula S,Prabhu RS,Nanda R,et al. Outcomes after radiation therapy to metastatic sites in patients with stage 4 neuroblastoma[J].J Pediat Hematol Oncol,2015,37(1):175-180.DOI:10.1097/MPH.0000000000000264. [3] Stenman J,Herold N,Svensson PJ,et al. Improved local control by extensive surgery in high-risk neuroblastoma may be dependent on adjuvant radiotherapy[J].J Clin Oncol, 2017,35(1):1965-1966.DOI:10.1200/JCO.2016.72.1175. [4] Smith V,Foster J.High-risk neuroblastoma treatment review[J].Children,2018,5.DOI:10.3390/children5090114. [5] Yang X,Chen J,Wang N,et al. Impact of extent of resection on survival in high-risk neuroblastoma:a systematic review and meta-analysis[J].J Pediat Surg,2018,53(9):1753-1760.DOI:10.1016/j.jpedsurg.2018.08.046. [6] Simon T,Haberle B,Hero B,et al. Role of surgery in the treatment of patients with stage 4 neuroblastoma age 18 months or older at diagnosis[J].J Clin Oncol,2013,31(3):752-758.DOI:10.1200/JCO.2012.45.9339. [7] Tian XD,Cao YN,Wang J,et al. A single center clinical analysis of children with high-risk neuroblastoma[J].Oncotarget,2017,8(18):30357-30368.DOI:10.18632/oncotarget.15996. [8] UeharaS,YonedaA,OueT,etal. Role of surgery in delayed local treatment for INSS 4 neuroblastoma[J].Pediat Int,2017,59(5),986-990.DOI:10.1111/ped.13349. [9] Li R,Polishchuk A,DuBois S,et al. Patterns of relapse in high-risk neuroblastoma patients treated with and without total body irradiation[J].Int JRadiat Oncol Biol Phys,2017,97(2):270-277.DOI:10.1016/j.ijrobp.2016.10.047. [10] Mazloom A,Louis CU,Nuchtern J,et al. Radiation therapy to the primary and postinduction chemotherapy MIBG-avid sites in high-risk neuroblastoma[J].Int JRadiat Oncol Biol Phys,2014,90(8):858-62.DOI:10.1016/j.ijrobp.2014.07.019. [11] Casey DL,Pitter KL,Kushner BH,et al. Radiation therapy to sites of metastatic disease as part of consolidation in high-risk neuroblastoma:can long-term control be achieved?[J].Int JRadiat Oncol Biol Phys, 2018,100(6):1204-1209.DOI:10.1016/j.ijrobp.2018.01.008. [12] Kandula S,Sutter A,Prabhu RS,et al. Reassessing dose constraints of organs at risk in children with abdominal neuroblastoma treated with definitive radiation therapy:a correlation with late toxicity[J].Pediat Blood Cancer,2015,62(5):970-975.DOI:10.1002/pbc.25372. [13] Beckham TH,Casey DL,LaQuaglia MP,et al. Renal function outcomes of high-risk neuroblastoma patients undergoing radiation therapy[J].Int J Radiat Oncol Biol Phys,2017,99(3):486-493.DOI:10.1016/j.ijrobp.2017.04.003. [14] Ducassou A,Gambart M,Munzer C,et al. Long-term side effects of radiotherapy for pediatric localized neuroblastoma:results from clinical trials NB90 and NB94[J].Strahlenther Onkol,2015,191(3):604-612.DOI:10.1007/s00066-015-0837-z. [15] Yu JI,Lim DH,Jung SH,et al. The effects of radiation therapy on height and spine MRI characteristics in children with neuroblastoma[J].Radiother Oncol,2015,114(2):384-388.DOI:10.1016/j.radonc.2015.02.016.
2019, Vol. 28 
